Because of the appalling prognoses associated with HGG such as GBM and DPIG, novel imidazotetrazine analogues or drug delivery formulations that can deliver an alkylating agent to O6-guanine that is neither removed by MGMT nor tolerated by MMR-deficient tumours are attractive prospects for future treatment. Here, MRC1 is linked to neoplasm.